GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RemeGen Co 9995.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

70.40

+0.28%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥3.76bn

FY2018FY2025

Net income

CN¥818.8m

FY2018FY2025

Free cash flow

−CN¥166.2m

FY2018FY2025

Shareholders' equity

CN¥2.68bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueCN¥3.76bnCN¥1.98bnCN¥1.25bnCN¥892.3mCN¥1.65bn−CN¥561,303CN¥3.1mCN¥13.1m
Research and developmentCN¥1.41bnCN¥1.80bnCN¥1.84bnCN¥1.13bnCN¥821.6mCN¥538.3mCN¥406.9mCN¥250.1m
Operating incomeCN¥833.7m−CN¥1.63bn−CN¥1.74bn−CN¥1.15bnCN¥188.2m−CN¥817.8m−CN¥446.8m−CN¥281.0m
Net incomeCN¥818.8m−CN¥1.70bn−CN¥1.75bn−CN¥1.15bnCN¥319.3m−CN¥806.4m−CN¥497.3m−CN¥312.0m
Diluted earnings per share1.50-3.16-3.23-2.070.66-1.65-1.04-0.65

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsCN¥8.38bnCN¥6.35bnCN¥6.39bnCN¥6.96bnCN¥4.81bnCN¥4.76bnCN¥796.6mCN¥613.8m
Cash and short-term investmentsCN¥2.80bnCN¥877.8mCN¥819.4mCN¥2.39bnCN¥2.03bnCN¥3.20bnCN¥43.3mCN¥7.0m
Total liabilities−CN¥2.68bnCN¥4.06bnCN¥2.42bnCN¥1.20bnCN¥823.7mCN¥604.5mCN¥1.06bnCN¥1.19bn
DebtCN¥2.52bnCN¥2.68bnCN¥1.28bnCN¥286.8mCN¥102.8mCN¥197.7mCN¥65.4mCN¥4.5m
Shareholders' equityCN¥2.68bnCN¥2.30bnCN¥3.97bnCN¥5.76bnCN¥3.98bnCN¥4.15bn−CN¥268.1m−CN¥575.7m
Shares outstanding547m536m540m556m485m490m478m478m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operationsCN¥65.0m−CN¥1.36bn−CN¥1.74bn−CN¥1.46bnCN¥304.7m−CN¥762.8m−CN¥326.8m−CN¥148.0m
Capital spending−CN¥231.1m−CN¥305.8m−CN¥985.5m−CN¥875.4m−CN¥713.4m−CN¥555.7m−CN¥75.4m−CN¥96.8m
Free cash flow−CN¥166.2m−CN¥1.67bn−CN¥2.72bn−CN¥2.34bn−CN¥408.8m−CN¥1.32bn−CN¥402.1m−CN¥244.7m
Dividends paid—−CN¥80.7m−CN¥17.8m—————

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
RevenueCN¥1.77bnCN¥718.7mCN¥661.0mCN¥607.8mCN¥587.1mCN¥539.8mCN¥475.3mCN¥381.9m
Operating incomeCN¥1.45bn−CN¥111.1m−CN¥221.2m−CN¥288.6m−CN¥462.0m−CN¥328.6m−CN¥493.0m−CN¥398.6m
Net incomeCN¥1.46bn−CN¥116.9m−CN¥225.8m−CN¥293.7m−CN¥458.7m−CN¥336.3m−CN¥498.7m−CN¥403.2m
Diluted earnings per share2.66-0.21-0.41-0.54-0.86-0.63-0.93-0.75
Cash from operations−CN¥187.0mCN¥535.0m−CN¥66.0m−CN¥217.0m−CN¥321.0m−CN¥17.0m−CN¥455.0m−CN¥492.0m
Capital spending−CN¥28.0m−CN¥63.0m−CN¥98.0m−CN¥41.0m−CN¥98.0m−CN¥44.0m−CN¥60.0m−CN¥103.0m
Free cash flow−CN¥215.0mCN¥472.0m−CN¥164.0m−CN¥258.0m−CN¥419.0m−CN¥61.0m−CN¥515.0m−CN¥595.0m
Total assetsCN¥8.38bnCN¥6.91bnCN¥6.76bnCN¥6.13bnCN¥6.35bnCN¥6.60bnCN¥6.65bnCN¥6.33bn
Cash and short-term investmentsCN¥2.80bnCN¥1.36bnCN¥1.48bnCN¥834.1mCN¥881.2mCN¥1.07bnCN¥1.01bnCN¥719.7m
DebtCN¥2.52bnCN¥1.69bnCN¥3.06bnCN¥1.89bnCN¥3.11bnCN¥1.32bnCN¥2.70bnCN¥731.9m
Shareholders' equityCN¥2.68bnCN¥2.68bnCN¥2.72bnCN¥2.05bnCN¥2.30bnCN¥2.74bnCN¥3.08bnCN¥3.56bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin3.7%-83.0%-139.5%-137.3%19.8%-2424.2%
Net margin21.9%-85.5%-140.4%-130.0%19.4%-2490.7%
Return on equity19.7%-73.9%-44.0%-20.0%8.0%-20.2%
Return on assets9.8%-26.7%-27.3%-16.6%6.6%-17.7%
Free cash flow yield0.6%-2.0%-1.5%-1.2%2.3%-0.5%
Revenue growth88.8%59.5%40.2%-46.1%4777.7%—
Earnings growth-148.3%-2.8%51.5%-461.2%-138.0%53.4%
Current ratio1.43x1.05x1.96x3.60x3.73x6.90x
Debt to equity0.60x1.32x0.34x0.03x-0.10x0.03x
Equity ratio49.8%36.1%62.2%82.7%82.9%87.3%
Interest coverage1.75x-19.68x-65.03x-156.00x52.90x-24.21x
R&D as a share of sales33.2%90.6%121.4%127.9%49.9%1595.7%
Buybacks as a share of market value-2.1%0.7%2.9%-14.6%0.9%-2.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue61.5%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-13.8%-46.6%-45.2%—
Net margin-15.3%-47.9%-44.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings41.6-3.9-10.0-24.2102.4-49.9
Price to sales9.13.414.031.319.9-71659.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.